Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria: Effects on Soluble TWEAK, PTX3, and Flow-Mediated Dilation

Mahmut Ilker Yilmaz,* Juan Jesús Carrero,† Jose Luis Martín-Ventura,‡ Alper Sonmez,§ Mutlu Saglam,‖ Turgay Celik,§ Halil Yaman,** Mujdat Yenicesu,* Tayfun Eyileten,* Juan Antonio Moreno,‡ Jesús Egido,‡ and Luis Miguel Blanco-Colio‡

*Department of Nephrology, Gülhane School of Medicine, Ankara, Turkey; †Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; ‡Vascular and Renal Research Laboratory, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz, Autonoma University, Madrid, Spain; and Departments of §Endocrinology, ¶Cardiology, and **Biochemistry, Gülhane School of Medicine, Ankara, Turkey

Background and objectives: Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3.

Design, setting, participants, & measurements: One-hundred-eight diabetic CKD stage I patients with hypertension (56% men, 46.7 ± 5.3 years) were allocated to a 12-week intervention with amlodipine (10 mg/d), valsartan (160 mg/d), or their combination. Plasma levels of sTWEAK, PTX3, and flow-mediated dilation (FMD) were studied during the interventions.

Results: All treatment strategies effectively increased FMD and reduced proteinuria, confirming a more prone reduction with the combined therapy. These improvements were followed by significant PTX3 reductions. Valsartan alone and in combination with amlodipine achieved significant incremental raises in sTWEAK plasma levels. More importantly, the changes observed in sTWEAK (β = 0.25, P = 0.006) or PTX3 (β = −0.24, P = 0.007) plasma levels were independently associated with the improvement in ultrasonographically measured FMD.

Conclusions: This study shows that treatment with antihypertensive drugs improves FMD and normalizes proteinuria, PTX3, and stWEAK in diabetic CKD stage I patients with hypertension. The improvement in FMD was independently associated with PTX3 and stWEAK normalization. Two surrogate biomarkers of endothelial function are therefore identified with potential as therapeutic targets. The study was registered in clinicaltrials.gov as NCT00921570.


Chronic kidney disease (CKD) patients die at a markedly accelerated rate, principally from cardiovascular disease (CVD) (1). The mechanisms for the elevated CVD risk in CKD are complex and may involve changes in the heart and vasculature already at early stages. Endothelial dysfunction (ED) is commonly observed along the CKD spectrum, being an obligatory prodromal phase in the atherosclerosis process that likely precedes other cardiovascular complications (2). Hypertension closely associates with ED and is a negative feature in all progressive renal diseases, especially diabetic nephropathy. Patients with a history of hypertension and kidney disease or diabetes are recommended to have an annual check for albuminuria and, if elevated (>200 mg/d), strategies for blood pressure (BP) lowering therapy should be taken (3). Use of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs), strict glycemic control, and antilipidemic drugs may in this way show improvements in retarding diabetic nephropathy progression (4). However, combined therapy with angiotensin II (AII) receptor blocker and calcium channel blockers has been suggested to provide additional advantages (5,6).

Long pentraxin-3 (PTX3) is a multimeric mediator that shares structural homology with hepatic short pentraxins such as C-reactive protein (CRP) and serum amyloid P component, but it is expressed by many cell types in response to different stimuli (7). Although PTX3 levels are known to be increased in individual with impaired renal function, it may share strong independent links with ED and albuminuria, perhaps contributing to increase the cardiovascular and mortality risk (8–10).
TNF-like weak inducer of apoptosis (TWEAK) is a type II transmembrane glycoprotein of the TNF superfamily that circulates in plasma as a soluble form (sTWEAK) with a molecular weight of 18 kD (11–13). TWEAK is widely expressed in many tissues including heart, skeletal muscle, and kidney (11,14). Binding of TWEAK to its receptor, Fn14 (13), mediates multiple biologic effects such as cellular growth, proliferation, and migration; osteoclastogenesis; angiogenesis; and apoptosis (15–17). sTWEAK plasma levels decrease with impaired renal function and associate with the aggravation of the endothelial function and the mortality risk (18,19). In the same line, diminished sTWEAK levels have been reported in patients with subclinical atherosclerosis (20).

A recent report was published by our group demonstrating that short-term ACE-inhibitor treatment significantly improved flow-mediated dilation (FMD) and normalized PTX3 and urinary protein excretion in type 2 diabetic patients with proteinuria (21). It is presently unknown whether sTWEAK levels can be normalized by short-term pharmacologic treatment. In the study presented here, we aimed to test the hypothesis that the previously demonstrated improvement in ED after initiation of ACE inhibitor blocker (valsartan) (22), calcium channel blocker (amlodipine) (23) therapy, or a combination of both (6) is directly linked to the normalization of PTX3 and sTWEAK. We tested this in 108 type 2 diabetic hypertensive proteinuric patients.

Materials and Methods

Patients and Controls

A randomized prospective study was performed with patients referred to the outpatient clinics at the Department of Nephrology of the Gulhane School of Medicine in Ankara, Turkey, during the period of June 2008 to June 2009. From these referrals, after a 24-hour urine collection, we selected patients with CKD stage 1 (24-hour protein excretion 1 to 2 g/d) who were older than 18 years of age, were willing to participate, and characterized as having type 2 diabetes mellitus as the only cause of nephropathy (renal biopsy and medical history) and hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg). A total of 375 patients fulfilled the above inclusion criteria, but 371 patients met all study criteria and were included in this study. The duration of proteinuria and diabetic nephropathy after initial diagnosis was not known.

We also recruited 35 healthy subjects to serve as controls. They had no known diseases and were not currently taking any drugs. Also, they were subject to the same inclusion and exclusion criteria as the patients. The informed consent to participate in the study was obtained from patients and controls. The drug ethical committee of the Gulhane School of Medicine approved the study. The study was registered in clinicaltrials.gov with the reference number NCT00921570.

Baseline Characterization

Recruited patients were evaluated by standard physical examination; chest x-ray; baseline ECG; two-dimensional echocardiography; and routine clinical laboratory tests, including liver and kidney function tests and 24-hour urinary protein measurements. Arterial BP was measured in the right arm by a mercury sphygmomanometer 3 times in a resting condition in the morning, and mean values were calculated for diastolic and systolic pressures. The exclusion criteria were as follows: nephrotic syndrome (renal protein excretion >3000 mg/d), coronary heart disease (patients with ischemic ST-T wave changes in ECG alterations, voltage criteria for left ventricular hypertrophy, and a history of revascularization or myocardial infarction), elevated liver enzymes (aspartate amino transferase or alanine amino transferase levels ≥40 U/L), and renal failure (serum creatinine levels >1.3 mg/dL). GFR was calculated according to the simplified version of the Modification of Diet in Renal Disease study prediction equation formula as defined by Levey (24).

Intervention and Follow-Up Measurements

Patients were randomized to one of the following intervention protocols that were given as a (1) AII receptor blocker (valsartan, 160 mg once per day), (2) calcium channel blocker (amlodipine, 10 mg once per day), or (3) their combination (valsartan 160 mg + amlodipine 10 mg once per day) for 12 weeks immediately after baseline measurements. During the study period, serum creatinine and potassium concentrations were measured every 2 weeks and the dose of valsartan was titrated to achieve a serum potassium concentration <5.5 mEq/L. After this period, blood samples were again obtained for measurements as shown below. Urine samples were also collected over 24 hours to determine the degree of proteinuria after intervention.

Laboratory Measurements

After an overnight fasting, venous blood samples from patients and controls were obtained to calculate fasting plasma glucose, serum albumin, total serum cholesterol, TG, and HDL and LDL cholesterol. Total plasma cholesterol, TG, and HDL cholesterol were measured by enzymatic colorimetric method with Olympus AU 600 autoanalyzer using reagents from Olympus Diagnostics, GmbH (Hamburg, Germany). LDL cholesterol was calculated by Friedewald’s formula (25). Plasma PTX3 concentration was measured from frozen samples using a commercially available ELISA kit (Perseus Proteomics, Inc., Japan). The same was true for plasma concentrations of sTWEAK, determined in duplicate with commercially available ELISA kits (Bender MedSystems, Vienna, Austria). Basal insulin level was measured by the coated tube method (DPC, United States). An insulin resistance score Homeostasis Model Assessment-Insulin resistance (HOMA-IR) was computed by the following formula (26): HOMA-IR = fasting plasma glucose (mg/dL) × immunoreactive insulin (µIU/mL)/405. Serum samples were diluted with a ratio of 1:101 with the diluents solution and high-sensitivity CRP (hsCRP) was measured as described previously (8).

Vascular Assessment

According to the method of Celermajer et al. (27) the endothelium-dependent vasodilatation (FMD) and endothelium-independent vasodilation (NMD) of the brachial artery were assessed by using high-resolution ultrasound. Measurements were made by a single observer using an Advanced Technology Laboratories 5000 ultrasound system (Bothell, WA) with a 12-Mhz probe. All vasoactive medications were withheld for 24 hours before the procedure. The subjects remained at rest in the supine position for at least 15 minutes before the examination started. The subject’s arm was comfortably immobilized in the ex-
tended position to allow consistent recording of the brachial artery 2 to 4 cm above the antecubital fossa. Three adjacent measurements of end-diastolic brachial artery diameter were made from single two-dimensional frames. All ultrasound images were recorded on S-VHS videotape for subsequent blinded analysis. A pneumatic tourniquet was inflated to 200 mmHg with obliteration of the radial pulse. After 5 minutes, the cuff was deflated. Flow measurements were made at 60 seconds postdeflation. After a further 15 minutes, measurements were repeated and again 3 minutes after administration of sublingual glyceryl trinitrate 400 µg per os. The maximum FMD and NMD dilation diameters were calculated as the average of the three consecutive maximum diameter measurements. The FMD and NMD were then calculated as the percent change in diameter compared with baseline resting diameters.

Statistical Analyses

Non-normally distributed variables were expressed as median (range) and normally distributed variables were expressed as mean ± SD as appropriate. P < 0.05 was considered to be statistically significant. Between-group comparisons were assessed for nominal variables with the χ² test. Differences induced by treatment were analyzed by paired t test. Differences among the groups were analyzed by a one-way ANOVA test followed by a post hoc Tukey–Kramer test for multiple comparisons. Pearson rank correlation was used to determine correlations between two variables. Stepwise multivariate regression analysis was used to assess predictors of specific changes before and after intervention. All of the statistical analyses were performed using the SPSS 11.0 (SPSS, Inc., Chicago, IL) statistical package.

Results

Effects of Amlodipine, Valsartan, and Their Combination on FMD, sTWEAK, and PTX3 Concentrations

As compared with healthy individuals with similar age, BMI, and GFR, patients presented increased hsCRP protein and PTX3 levels and reduced FMD and sTWEAK values at the beginning of the study (Table 1). Patients were randomized to the three intervention groups, being well balanced with regards to age, sex distribution, BMI, estimated GFR, and 24-hour proteinuria. Baseline biochemistry, FMD values, and PTX3 or sTWEAK plasma concentrations were not different across these groups (Table 2). During the 12-week study period, ten patients were excluded because of the AII receptor blocker or calcium channel blocker treatment side effects (cough, n = 1; hyperkalemia, n = 2; edema, n = 3) or incompliance (n = 4).

Changes induced in different arms during the 12-week study periods are summarized in Table 2 and in Figure 1. Briefly, proteinuria diminished after all interventions, observing the highest improvement in the patients that received the combined therapy. FMD was improved and PTX3 was reduced after all interventions, but the effect observed in the group treated with the combined therapy did not differ from that of valsartan alone. sTWEAK levels did not vary after amlodipine intervention. Nonetheless, treatment with valsartan alone or combined with amlodipine resulted in higher sTWEAK values.

Univariate and Multivariate Correlations

At the beginning of the study, and pooling all patients, FMD was negatively associated with hsCRP (rho = −0.21; P = 0.03) and PTX3 (rho = −0.39; P < 0.001) concentrations (Figure 2A) but positively correlated with sTWEAK (rho = 0.45; P < 0.001) (Figure 2B). These associations persisted after treatment and were also true for each treatment subgroup of patients (data not shown). Univariate and multivariate associations of the treatment-induced changes in diverse parameters are shown in Table 3. Briefly, the percent increase in FMD was negatively associated with the reductions in diastolic BP, hsCRP, and PTX3, but positively correlated with sTWEAK (rho = 0.39; P < 0.001) concentrations (Figure 2D).

We used a multiple linear regression model to analyze the independent contributors to the changes in FMD. This model included age and sex, as well as variables significantly associated with FMD in univariate analysis. After stepwise exclusion, the increase in FMD was multivariably explained by the improvement in diastolic BP, the reductions in hsCRP and PTX3, and the sTWEAK increase (r² of the model = 0.17).

Discussion

In this study, we report the effects of an open-label, 12-week pharmacologic intervention trial analyzing the effect of initiation with amlodipine, valsartan, or their combination on diabetic proteinuric subjects with hypertension. We found that all

Table 1. General characteristics of patients included in the study and compared to healthy individuals

<table>
<thead>
<tr>
<th>Group</th>
<th>Healthy (n = 35)</th>
<th>Patients (n = 108)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>46 ± 5</td>
<td>48 ± 7</td>
<td>0.3</td>
</tr>
<tr>
<td>Gender, male/female</td>
<td>17/18</td>
<td>51/57</td>
<td>0.8</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26 (22 to 30)</td>
<td>27 (21.5 to 30)</td>
<td>0.6</td>
</tr>
<tr>
<td>Estimated GFR, ml/min/1.73 m²</td>
<td>112 ± 7.7</td>
<td>113 ± 8.9</td>
<td>0.4</td>
</tr>
<tr>
<td>24-hour proteinuria, mg/d</td>
<td>40 (10 to 90)</td>
<td>1590 (600 to 2800)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FMD, %</td>
<td>8.8 (7.6 to 12.4)</td>
<td>6.4 (5.5 to 8.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NMD, %</td>
<td>13.4 (11.8 to 13.9)</td>
<td>13 (11.8 to 13.8)</td>
<td>0.01</td>
</tr>
<tr>
<td>hsCRP, mg/L</td>
<td>2.4 ± 0.8</td>
<td>12.9 ± 4.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PTX3, ng/ml</td>
<td>1.3 (0.1 to 2.7)</td>
<td>7.7 (1.8 to 32.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>sTWEAK, pg/ml</td>
<td>472 ± 81</td>
<td>411 ± 77</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD, median (25th to 75th percentile), or number of patients.
<table>
<thead>
<tr>
<th>Group</th>
<th>Amlodipine (n = 35)</th>
<th>Valsartan (n = 37)</th>
<th>Amlodipine + Valsartan (n = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>After</td>
<td>Before</td>
</tr>
<tr>
<td>Age, years</td>
<td>47 ± 5</td>
<td>–</td>
<td>47 ± 9</td>
</tr>
<tr>
<td>Gender, male/female</td>
<td>16/19</td>
<td>–</td>
<td>17/20</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.2 ± 2.1</td>
<td>–</td>
<td>26.5 ± 1.9</td>
</tr>
<tr>
<td>Estimated GFR, ml/min/1.73 m²</td>
<td>115 ± 8.6</td>
<td>105 ± 12&lt;sup&gt;c&lt;/sup&gt;</td>
<td>112 ± 8.4</td>
</tr>
<tr>
<td>24-hour proteinuria, mg/d</td>
<td>1560 (600 to 2800)</td>
<td>1200 (200 to 2130)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1560 (780 to 2700)</td>
</tr>
<tr>
<td>Serum albumin, g/dl</td>
<td>3.8 ± 0.3</td>
<td>4 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4 ± 0.3</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>180 ± 23</td>
<td>157 ± 31&lt;sup&gt;b&lt;/sup&gt;</td>
<td>179 ± 36</td>
</tr>
<tr>
<td>TG, mg/dl</td>
<td>135 ± 13</td>
<td>121 ± 23&lt;sup&gt;b&lt;/sup&gt;</td>
<td>135 ± 25</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>120 ± 27</td>
<td>97 ± 28&lt;sup&gt;b&lt;/sup&gt;</td>
<td>118 ± 24</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>37 ± 6</td>
<td>41 ± 5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>39 ± 7</td>
</tr>
<tr>
<td>Plasma insulin, mIU/ml</td>
<td>5.2 (3.8 to 7.3)</td>
<td>4.2 (2.1 to 5.8)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.2 (3.6 to 8)</td>
</tr>
<tr>
<td>Plasma glucose, mg/dl</td>
<td>162 (115 to 214)</td>
<td>153 (115 to 213)</td>
<td>169 (107 to 219)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.1 ± 0.5</td>
<td>1.6 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>2.3 ± 0.6</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>150 (140 to 165)</td>
<td>130 (110 to 137)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>148 (133 to 160)</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>90 (80 to 98)</td>
<td>80 (70 to 91)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>92 (82 to 100)</td>
</tr>
<tr>
<td>hsCRP, mg/L</td>
<td>11.8 ± 4.5</td>
<td>8.1 ± 3.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>13.2 ± 4.6</td>
</tr>
<tr>
<td>PTX3, ng/ml</td>
<td>6.5 (1.8 to 33)</td>
<td>2.5 (1.6 to 16)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>8.5 (1.8 to 33)</td>
</tr>
<tr>
<td>sTWEAK, pg/ml</td>
<td>418 ± 71</td>
<td>418 ± 77</td>
<td>407 ± 77</td>
</tr>
<tr>
<td>FMD, %</td>
<td>6.7 (5.5 to 8.3)</td>
<td>7.5 (5 to 8.7)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6.3 (5.5 to 8)</td>
</tr>
<tr>
<td>NMD, %</td>
<td>13 (12.1 to 13.7)</td>
<td>13 (12 to 13.8)</td>
<td>13 (11.8 to 13.8)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD and median (range). HOMA, homeostasis model assessment.

<sup>a</sup>Paired <i>t</i> test, <i>P</i> < 0.05.

<sup>b</sup>Paired <i>t</i> test, <i>P</i> < 0.01.

<sup>c</sup>Paired <i>t</i> test, <i>P</i> < 0.001.
treatment strategies effectively increased FMD and reduced proteinuria, confirming a more prone reduction with the combined therapy. These improvements were also followed by PTX3 reductions. Interestingly, valsartan alone and in combination with amlodipine achieved significant raises in sTWEAK plasma levels. More importantly, the changes observed in sTWEAK or PTX3 plasma levels were independently associated with the improvement in ultrasonographically measured FMD.

On one hand, our results evidence the possible role of PTX3 on local vascular health and proteinuria. PTX3 is a recently described multimeric inflammatory mediator structurally linked to CRP. As opposed to CRP, exclusively derived from hepatocytes, PTX3 is synthesized by various tissues and cells, including vascular endothelial cells (28) and macrophages (29), thus reflecting local tissue inflammatory activity. In the study presented here and in previous studies, we have shown that PTX3 levels are elevated across the CKD spectrum (8,9), and that in dialysis patients PTX3 predicts mortality independent of traditional risk factors and CRP (10,21). Strengthening our previous reports (8,21), results from the study presented here demonstrate that PTX3 is a strong and independent determinant of proteinuria and ED, as demonstrated here in a cross-sectional manner and longitudinally through pharmacologic intervention. Renin-angiotensin system blockers (21) and calcium channel blockers normalized PTX3 levels, but no additive reduction effect was observed with the combination of these drugs.

**Figure 1.** Changes in proteinuria, FMD, PTX3, and sTWEAK (delta values) after a 12-week treatment with different antihypertensive therapies. *P < 0.05 versus amlodipine; †P < 0.05 versus valsartan.

**Figure 2.** Scatterplots showing the univariate associations between FMD and (A) PTX3 or (B) sTWEAK before treatment, as well as the association of 12-week changes in FMD with (C) the reduction in PTX3 and (D) the increase in sTWEAK.
relevant parameters between intervention-induced changes (D) in FMD and lesion size and a higher inflammatory response compared with mice lacking ApoE and PTX3 displayed an increment in aortic erosclerotic lesions and implicated on neointimal thickening sTWEAK. Several studies implicate both molecules in the wors-
changes, with these associations being somewhat stronger for demonstration in multivariate analysis that the improvement in sTWEAK plasma concentrations after a 12-week intervention.

Patients (40). Our results now show that treatment with valsar-
jects with subclinical atherosclerosis, diabetic subjects, CKD expectedly, lower plasma sTWEAK has been reported in sub-
ers, vascular smooth muscle cells, macrophages, and tubular and glo-
receptor of sTWEAK, CD163, which under proinflammatory
least in part, by the presence of a newly reported scavenger
peptide (37) and contributed to improve the prediction of cor-
incidence in a model of atherosclerosis in mice (35), and treatment
jection of human recombinant sTWEAK increased lesion develop-
ment in a model of arteriosclerosis in mice (35), and treatment
with Fn14-Fc diminished atherosclerotic lesion size in ApoE
knockout mice (44). However, it is important to note that our
study was not designed to explain the mechanisms behind
these associations and we cannot exclude the possibility of a reverse causality, whereby lower BP leads to lower levels of systemic inflammation. AII is an important inductor of vascular injury by inducing ED, promoting vascular remodeling, and accelerating atherosclerotic plaque development (45). At the same time, restoration of calcium homeostasis in the vascula-
ture may improve vascular resistance and structural arterial wall reorganization (46). It is thus possible that an increase of AII concentrations and/or inhibition of calcium channels linked to hypertension could be responsible for reduced local inflammation, thereby explaining the observed changes in PTX3 and sTWEAK.

Some limitations should be considered in this study. First, the
number of subjects included in each group of treatment was small. Second, factors that were not controlled for (e.g., glycemic control) could reasonably also affect endothelial function and proteinuria. Third, because we evaluated a specifically selected group of type 2 diabetic CKD stage 1 patients who do not represent the heterogeneous CKD patient population at large, these results need confirmation in other studies. Finally, because of the nature of the study design, it is unclear if the normalization observed in sTWEAK and PTX3 levels are be-
cause of changes in systolic BP or because of specific cellular properties from specific effects of the pharmacologic agents used.

In summary, we observe that a 12-week treatment with an-
thyhypertensive drugs significantly reduced PTX3 and increased sTWEAK concentrations. These changes were associated with an increase in FMD and a reduction in proteinuria. In addition to adding to the wealth of evidence linking treatment with ACE inhibitors and calcium channel blockers to beneficial vascular
and anti-inflammatory effects in diabetic kidney disease, our study may also indicate that, at least in theory, these drugs could mediate their actions through PTX3 and sTWEAK mod-
ulation. This may encourage further mechanistic research re-
arding the potential of these molecules as therapeutic targets in inflammation- or atherosclerosis-related diseases.

**Table 3. Univariate and multivariate associations between intervention-induced changes (D) in FMD and relevant parameters**

<table>
<thead>
<tr>
<th></th>
<th>ΔFMD</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>r (P)</td>
<td>b (P)</td>
</tr>
<tr>
<td>ΔeGFR, ml/min/1.73 m²</td>
<td>0.21 (0.03)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>ΔSBP, mmHg</td>
<td>−0.22 (0.02)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>ΔDBP, mmHg</td>
<td>−0.26 (0.006)</td>
<td>−0.22 (0.01)</td>
<td></td>
</tr>
<tr>
<td>ΔHOMA-IR</td>
<td>−0.22 (0.02)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>ΔhsCRP, mg/L</td>
<td>−0.27 (0.005)</td>
<td>−0.2 (0.04)</td>
<td></td>
</tr>
<tr>
<td>ΔFMD, %</td>
<td>0.22 (0.02)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔPTX3, ng/ml</td>
<td>−0.27 (0.005)</td>
<td>−0.24 (0.007)</td>
<td></td>
</tr>
<tr>
<td>ΔsTWEAK, pg/ml</td>
<td>0.30 (0.002)</td>
<td>0.25 (0.006)</td>
<td></td>
</tr>
<tr>
<td>Δ24-hour proteinuria</td>
<td>−0.27 (0.005)</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

SBP, systolic BP; DBP, diastolic BP.

However, this is the first time in which the effect of a drug intervention on sTWEAK has been evaluated. TWEAK has been recently implicated in the development of vascular and renal damage (30–33), being expressed in endothelial and vascular smooth muscle cells, macrophages, and tubular and glomerular cells (31,34). The binding of TWEAK to its receptor Fn14 increases the inflammatory response associated with atherosclerotic plaque development and renal lesions (32,35). Unexpectedly, lower plasma sTWEAK has been reported in subjects with subclinical atherosclerosis, diabetic subjects, CKD patients (18–20,36), and in this study. In CKD patients, sTWEAK appeared to be robustly and negatively associated with ED (19), and sTWEAK plasma concentrations were good prognosticators of all-cause and CVD mortality in patients undergoing hemodialysis (18). Interestingly, in patients with chronic stable heart failure, reduced sTWEAK levels predicted an adverse prognosis independently of established risk markers such as the N-terminal prohormone of brain natriuretic peptide (37) and contributed to improve the prediction of coronary artery disease (38). These findings could be explained, at least in part, by the presence of a newly reported scavenger receptor of sTWEAK, CD163, which under proinflammatory conditions can sequester and degrade sTWEAK (39). In support of this, CD163 has been reported to be upregulated in CKD patients (40). Our results now show that treatment with valsartan alone, or in combination with amiodipine, normalized sTWEAK plasma concentrations after a 12-week intervention.

An important finding in the study presented here is the demonstration in multivariate analysis that the improvement in FMD was independently associated with sTWEAK and PTX3 changes, with these associations being somewhat stronger for sTWEAK. Several studies implicate both molecules in the worsening of endothelial function: PTX3 has been detected in atherosclerotic lesions and implicated on neointimal thickening (41,42). However, the recent observation that double knockout mice lacking ApoE and PTX3 displayed an increment in aortic lesion size and a higher inflammatory response compared with ApoE knockout mice expressing PTX3 (43) has lead to the hypothesis that PTX3 may be a failed compensatory mechanism to endothelial damage. On the other hand, systemic injection of human recombinant sTWEAK increased lesion development in a model of atherosclerosis in mice (35), and treatment with Fn14-Fc diminished atherosclerotic lesion size in ApoE knockout mice (44). However, it is important to note that our study was not designed to explain the mechanisms behind these associations and we cannot exclude the possibility of a reverse causality, whereby lower BP leads to lower levels of systemic inflammation. AII is an important inductor of vascular injury by inducing ED, promoting vascular remodeling, and accelerating atherosclerotic plaque development (45). At the same time, restoration of calcium homeostasis in the vasculature may improve vascular resistance and structural arterial wall reorganization (46). It is thus possible that an increase of AII concentrations and/or inhibition of calcium channels linked to hypertension could be responsible for reduced local inflammation, thereby explaining the observed changes in PTX3 and sTWEAK.

Some limitations should be considered in this study. First, the number of subjects included in each group of treatment was small. Second, factors that were not controlled for (e.g., glycemic control) could reasonably also affect endothelial function and proteinuria. Third, because we evaluated a specifically selected group of type 2 diabetic CKD stage 1 patients who do not represent the heterogeneous CKD patient population at large, these results need confirmation in other studies. Finally, because of the nature of the study design, it is unclear if the normalization observed in sTWEAK and PTX3 levels are because of changes in systolic BP or because of specific cellular properties from specific effects of the pharmacologic agents used.

In summary, we observe that a 12-week treatment with antihypertensive drugs significantly reduced PTX3 and increased sTWEAK concentrations. These changes were associated with an increase in FMD and a reduction in proteinuria. In addition to adding to the wealth of evidence linking treatment with ACE inhibitors and calcium channel blockers to beneficial vascular and anti-inflammatory effects in diabetic kidney disease, our study may also indicate that, at least in theory, these drugs could mediate their actions through PTX3 and sTWEAK modulation. This may encourage further mechanistic research regarding the potential of these molecules as therapeutic targets in inflammation- or atherosclerosis-related diseases.

**Acknowledgments**

This study was supported by the Gulhane School of Medicine Research Center. The authors were supported by grants from the Center of Gender Medicine at Karolinska Institutet, the Loo and Hans Osterman Foundation, the Swedish Kidney Association, Ministerio de Ciencia y Tecnología (SAF 2007/60986, SAF2007/63648), Comunidad de Madrid (S2016/GEN-0247), Fondo de Investigaciones Sanitarias (Programa Miguel Servet to L.M.B.-C.), Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, (RETICS RD06/0014/0035), and the Sociedad Española de Arteriosclerosis and Fundación Ramón Areces. M.I.Y and J.J.C contributed equally to this work.
Disclosures
None.

References
26. Matthews DR, Hosker JP, Rudetski AS, Naylor BA,


